# Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma

> **NCT01849146** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 74 (actual)

## Conditions studied

- Glioblastoma
- Recurrent Glioblastoma

## Interventions

- **DRUG:** Adavosertib
- **RADIATION:** Radiation Therapy
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT01849146
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-24
- **Primary completion:** 2021-07-29
- **Final completion:** 2024-10-30
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2025-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01849146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01849146, "Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01849146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*